Zacks Investment Research lowered shares of Abeona Therapeutics (NASDAQ:ABEO) from a buy rating to a hold rating in a research note published on Tuesday morning, Zacks.com reports.

According to Zacks, Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.

Other research analysts have also issued research reports about the stock. BidaskClub upgraded shares of Abeona Therapeutics from a sell rating to a hold rating in a research note on Monday, June 17th. Royal Bank of Canada lowered their price objective on shares of Abeona Therapeutics to $16.00 and set a positive rating on the stock in a research note on Tuesday, August 13th. They noted that the move was a valuation call. Cantor Fitzgerald lowered shares of Abeona Therapeutics from an overweight rating to a neutral rating in a research note on Monday, August 12th. Maxim Group lowered shares of Abeona Therapeutics from a buy rating to a hold rating in a research note on Thursday, August 15th. Finally, ValuEngine upgraded shares of Abeona Therapeutics from a hold rating to a buy rating in a research note on Wednesday, October 2nd. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $17.21.

NASDAQ ABEO opened at $2.71 on Tuesday. Abeona Therapeutics has a 12 month low of $1.46 and a 12 month high of $10.62. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.54 and a quick ratio of 2.54. The firm has a market capitalization of $110.47 million, a PE ratio of -2.28 and a beta of 1.95. The companys 50 day simple moving average is $2.51 and its 200 day simple moving average is $4.68.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Friday, August 9th. The biopharmaceutical company reported ($0.49) EPS for the quarter, missing the Zacks consensus estimate of ($0.36) by ($0.13). Sell-side analysts anticipate that Abeona Therapeutics will post -1.7 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of ABEO. Marshall Wace LLP grew its position in Abeona Therapeutics by 45.9% during the 2nd quarter. Marshall Wace LLP now owns 13,254 shares of the biopharmaceutical companys stock worth $63,000 after purchasing an additional 4,168 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Abeona Therapeutics by 434.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,719 shares of the biopharmaceutical companys stock valued at $42,000 after buying an additional 7,088 shares during the period. Northern Trust Corp boosted its stake in shares of Abeona Therapeutics by 2.0% during the 2nd quarter. Northern Trust Corp now owns 408,134 shares of the biopharmaceutical companys stock valued at $1,951,000 after buying an additional 7,824 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Abeona Therapeutics by 13.6% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 77,765 shares of the biopharmaceutical companys stock valued at $372,000 after buying an additional 9,281 shares during the period. Finally, Ardsley Advisory Partners LP boosted its stake in shares of Abeona Therapeutics by 33.3% during the 2nd quarter. Ardsley Advisory Partners LP now owns 40,000 shares of the biopharmaceutical companys stock valued at $190,000 after buying an additional 10,000 shares during the period. Hedge funds and other institutional investors own 58.71% of the companys stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Further Reading: What is a Futures Contract?

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

View original post here:
Abeona Therapeutics (NASDAQ:ABEO) Downgraded to Hold at Zacks Investment Research - Covington Journal

Comments are closed.